The Global Cardiovascular Risk Consortium (GCVRC) brings together harmonized individual-level data from currently more than 2 million (anticipated: approximately 3 million) individuals across 133 cohorts, 40 countries, and 6 continents, with recruitment ongoing. The GCVRC examines the impact of classical cardiovascular risk factors-such as body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes-on cardiovascular disease (CVD) and death from any cause worldwide.

A small number of modifiable risk factors accounts for a significant proportion of cardiovascular disease (CVD) risk. However, the CVD burden attributable to classical risk factors depends on the populations studied and the methodologies used.

The Global Cardiovascular Risk Consortium (GCVRC) is an international collaboration that continuously includes cohort studies from around the world to improve cardiovascular risk prediction. The GCVRC uses extensively harmonized individual-level data from currently more than 2 million individuals from 133 cohorts, 40 countries and 6 continents categorized in 8 geographical regions (based on a modification of WHO and United Nations definitions) - North America, Latin America, Sub-Saharan Africa, North Africa and the Middle East, Western Europe, Eastern Europe and Russia, Asia, and Australia.

The consortium has a special focus on classical, potentially modifiable cardiovascular risk factors: body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes. Key research questions include examining the impact of these factors on major outcomes by geographical region and sex, as well as estimating associated lifetime risk and the potential lifetime difference when modifying these risk factors.

This work is critical for developing regionally tailored CVD prevention and treatment strategies, identifying residual risk, and improving global cardiovascular health.

Based on GCVRC data, a paper on the effect of classical risk factors on new-onset CVD and all-cause mortality was published in the New England Journal of Medicine in 2023 (doi.org/10.1056/nejmoa2206916), followed by a study evaluating the effect of classical risk factors on different lifetime estimates, also published in the New England Journal of Medicine in 2025 (doi: 10.1056/NEJMoa2415879).

Further studies evaluate the effect of projecting risk factor reductions on CVD and all-cause mortality at the population level.

Inclusion Criteria:

Population-based individual-level data with available information on the classical cardiovascular risk factors including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes, as well as the outcomes of interest.

Exclusion Criteria:

• Participants with age below 18 years
• No information on the outcome of interest
• No information on the exposure of interest (CVD risk factors)
• History of CVD at baseline

The GCVRC uses harmonized individual-level data from currently more than 2 Mio individuals from 133 cohorts, 40 countries and 6 continents, categorized in 8 geographical regions - North America, Latin America, Sub-Saharan Africa, North Africa and the Middle East, Western Europe, Eastern Europe and Russia, Asia, and Australia.

The database provides information on cardiovascular risk factors, including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes, as well as data on major cardiovascular outcomes and death.